论文部分内容阅读
目的:选择HBeAg、HBVDNA均为阳性的慢性乙型肝炎患者62例,予肝灵素和胸腺肽联合治疗。方法:根据疗程分为3月组、9月组、12月组。结果:随着疗程增长,HBeAg、HBVDNA转阴率逐渐增加,舌下含化肝灵素至12月时,二者转阴率均为47.06%,已接近或达到较大剂量α-干扰素疗效;随访二年时,舌下含化肝灵素12月组转阴率稍有上升,并且HBeAg、HBVDNA转阴后复阳率随着疗程增长逐渐下降。因此,肝灵素和胸腺肽联合抗乙肝病毒治疗是有效的,建议疗程不应短于12个月。
OBJECTIVE: To select 62 patients with chronic hepatitis B who are positive for both HBeAg and HBVDNA, and to treat liver cancer with thymosin. Methods: According to the course of treatment were divided into March group, September group, December group. Results: With the course of treatment increasing, the negative conversion rate of HBeAg and HBVDNA gradually increased. When sublingual was given into the decoction of the liver until December, the negative conversion rate of both was 47.06%, which was close to or reached the effect of larger dosage of interferon-α At the follow-up of two years, the rate of negative conversion of sublingual venlafaxine in December increased slightly, and the positive rate of HBeAg and HBVDNA decreased gradually with the increase of treatment. Therefore, hepcidin and thymosin combined anti-hepatitis B virus treatment is effective, the recommended course of treatment should not be shorter than 12 months.